The nation's top health official challenged insurers on Wednesday to join President Barack Obama's push to overhaul the medical system, arguing that if the effort fails it will hurt them as well as other Americans. (Source: WDSU.com - Health)
Have newspaper columnists taken "pharma-bashing" too far? Medscape Ob/Gyn & Women's Health (Source: Medscape Today Headlines)
Authors: Saif MW, Kaley K, Lamb L, Pecerillo J, Hotchkiss S, Steven L, Brennan M, Penney R, Gillespie C, Shaib W
Erlotinib has been FDA approved to be used in combination with gemcitabine as the first line treatment in advanced pancreatic cancer patients. Skin rash has been documented as one of the commonest adverse reactions in patients receiving erlotinib and other EGFR inhibitors. Draw back to this reaction leads to: 1) drug discontinuation or dose reduction; 2) impairs quality of life; and 3) Puts patients at risk of superinfection. Monitoring patients closely and initiating immediate skin care is recommended. However, patients forget how the rash started and when. No standard treatments exist secondary to the diversity of symptoms, variability and intermittent occurrence in relati...
If the House concurs and President Obama signs the measure into law, it will be the third time in 4 months that lawmakers have postponed the reduction. Medscape Medical News (Source: Medscape Today Headlines)
Access to medication has not improved among Medicare beneficiaries with depressive symptoms despite efforts to do with the introduction of Medicare Part D. Medscape Medical News (Source: Medscape Today Headlines)